Everything below concerns RP-HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
=== Other research === In 2001, Sachs led a research team at UB which found that a chemical isolated from the venom of the Chilean tarantula could calm abnormal rhythms induced in rabbit hearts. Sachs said the result of this study showed that the protein could herald a new class of compounds that could be targeted at treating the causes, rather than the symptoms, of atrial fibrillation. Following this discovery, Sachs was named a UB Distinguished Professor and honored by Buffalo Business First for his invention. In 2013, Sachs and his research team identified that familial xerocytosis causes symptoms, such as the shortness of breath seen in anemic patients. This identification marked the first time defects in a mechanosensitive ion channel were implicated as the cause of a disease. Beyond spider venom, Sachs also conducted the first voltage clamp studies of isolated adult heart cells. He was also responsible for the first single-channel recording from tissue cultured cells.
=== Growth plate === PTHrP is found in the proliferative zone of the growth plate. It is one of the main proteins that regulates mesenchymal stem cell activity. Current research suggests that PTHrP promotes the proliferation of early-phase chondrocytes and inhibits their differentiation into hypertrophic chondrocytes. It is involved in a negative feedback loop with Indian Hedgehog (Ihh).
=== Interbellum (1918–1939) === Elements of the Army operated around Mary, Turkmenistan in 1918–19. See Malleson mission and Entente intervention in the Russian Civil War. The army then took part in the Third Anglo-Afghan War of 1919. In the aftermath of the First World War, the Indian Territorial Force and Auxiliary Force (India) were created in the 1920s. The Indian Territorial Force was a part-time, paid, all-volunteer organisation within the army. Its units were primarily made up of European officers and Indian other ranks. The ITF was created by the Indian Territorial Force Act 1920 to replace the Indian section of the Indian Defence Force. It was an all-volunteer force modelled after the British Territorial Army. The European parallel to the ITF was the Auxiliary Force (India). After the First World War the British started the process of Indianisation, by which Indians were promoted into higher officer ranks. In a 1923 census, the British Indian Army consisted of 64,669 British-born soldiers and officers, with 187,432 Indian-born soldiers in comparison. Indian cadets were sent to study in Great Britain at the Royal Military College, Sandhurst, and were given full commissions as King's Commissioned Indian Officers. The KCIOs were equivalent in every way to British commissioned officers and had full authority over British troops (unlike VCOs). Some KCIOs were attached to British Army units for a part of their careers.
Imidazole propionate (ImP), also known as 5-imidazolepropionic acid, is a bacterial metabolite of histidine and a neurotoxin. It is produced by Streptococcus mutans and its enzyme urocanate reductase (UrdA) in the gut. S. mutans, as well as ImP production and circulating levels, have been found to be elevated in people with Parkinson's disease. In addition, administration of ImP, or colonization with ImP-producing bacteria, causes dopaminergic neurotoxicity and Parkinson's disease-like symptoms in rodents. Based on these findings, UrdA-expressing and ImP-producing bacteria may be involved in the etiology of Parkinson's disease in humans. ImP has also been implicated in the pathophysiology of other diseases such as atherosclerosis, diabetes, and Alzheimer's disease, among others. ImP activates the imidazoline I1 receptor and this appears to be involved in some of its toxic effects. Relatedly, imidazoline I1 receptor antagonists have been proposed for possible therapeutic purposes.
Levamisole is one of the most common cutting agents used to lace illicit cocaine, with studies showing that between 2009 and 2016, 50–70% of all cocaine specimens worldwide contained levamisole, reflecting similar high rates of contamination across North America and Europe. Before trafficking to the United States, the cocaine is frequently adulterated with levamisole. By October 2017, this figure had risen further, with the US Drug Enforcement Administration (DEA) reporting that 87% of seized and analyzed cocaine bricks in the United States contained levamisole, making it the most common adulterant in cocaine at that time. In the body, levamisole is converted into aminorex, a substance with amphetamine-like stimulant effects and a long duration of action. Levamisole-adulterated cocaine is associated with cocaine/levamisole-associated autoimmune syndrome (CLAAS) and cocaine- and levamisole-induced vasculitis (CLIV). Reagent testing kits can be used to detect the presence of cocaine and levamisole.
Sources: en.wikipedia.org
A metallocene is a compound typically consisting of two cyclopentadienyl anions (C5H−5, abbreviated Cp) bound to a metal center (M). They have the general formula (C5R5)2M]+ (R = H, alkyl typically). Closely related to the metallocenes are the metallocene derivatives, e.g. titanocene dichloride or vanadocene dichloride. Certain metallocenes and their derivatives exhibit catalytic properties, although metallocenes are rarely used industrially. Cationic group 4 metallocene derivatives related to [Cp2ZrCH3]+ catalyze olefin polymerization. Metallocenes are a subset of a broader class of compounds called sandwich compounds. In the structure shown at right, the two pentagons are the cyclopentadienyl anions with circles inside them indicating they are aromatically stabilized. Here they are shown in a staggered conformation.
Compound 22 is a low-potency and non-selective trace amine-associated receptor 1 (TAAR1) antagonist that was identified in 2015 and was further studied in animals in 2018. The drug enhances the firing rates of dopaminergic neurons ex vivo and potentiates psychostimulant-induced hyperlocomotion and stereotypy in rodents in vivo. The latter effects are partially or fully independent of the TAAR1 however, with the mechanisms underlying these effects being unknown. Compound 22, along with EPPTB and RTI-7470-44, is one of the only TAAR1 antagonists that has been identified as of 2022.
7 July The first tandem perovskite-silicon solar cell to exceed 30% efficiency (31.25%) is independently certified by the National Renewable Energy Laboratory. A study into the effects of a global nuclear war on the world's oceans is published, revealing a rapid 10.5 °C (18.9 °F) drop in temperature, along with many longer-lasting impacts. 8 July – Astronomers report the discovery of massive amounts of prebiotic molecules, including precursors for RNA, in the Galactic Center of the Milky Way Galaxy. 9 July – Researchers report the development of an efficient, secure and convenient method to separate, purify, store and transport large amounts of hydrogen for energy storage in renewables-based energy systems as powder using ball milling. 11 July Researchers report the development of a deep learning system that learns intuitive physics from visual data (of virtual 3D environments) to some degree "from scratch" based on an unpublished approach inspired by studies of visual cognition in infants. On 25 July, other researchers report the development of a machine learning algorithm that could discover sets of basic variables of various physical systems and predict the systems' future dynamics from video recordings of their behavior. News outlets report about the development of algae biopanels by a company for sustainable energy generation with unclear viability after other researchers built the self-powered BIQ house prototype in 2013.
=== Purity and purification === TLC helps show the purity of a sample. A pure sample should only contain one spot by TLC. TLC is also useful for small-scale purification. Because the separated compounds will be on different areas of the plate, a scientist can scrape off the stationary phase particles containing the desired compound and dissolve them into an appropriate solvent. Once all the compound dissolves in the solvent, they filter out the silica particles, then evaporate the solvent to isolate the product. Big preparative TLC plates with thick silica gel coatings can separate more than 100 mg of material. TLC is useful for larger-scale purification and isolation to quickly test solvent mixtures before running flash column chromatography on a large batch of impure material. A compound elutes from a column when the amount of solvent collected is equal to 1/RF. The eluent from flash column chromatography gets collected across several containers (for example, test tubes) called fractions. TLC helps show which fractions contain impurities and which contain pure compound. Furthermore, two-dimensional TLC can help check if a compound is stable on a particular stationary phase. This test requires two runs on a square-shaped TLC plate. The plate is rotated by 90º before the second run. If the target compound appears on the diagonal of the square, it is stable on the chosen stationary phase. Otherwise, it is decomposing on the plate. If this is the case, an alternative stationary phase may prevent this decomposition.
Sources: en.wikipedia.org
Koichi Tanaka (田中 耕一, Tanaka Kōichi; born August 3, 1959) is a Japanese electrical engineer who shared the Nobel Prize in Chemistry in 2002 for developing a novel method for mass spectrometric analyses of biological macromolecules with John Bennett Fenn and Kurt Wüthrich (the latter for work in NMR spectroscopy).
=== High blood pressure === Valsartan and hydrochlorothiazide are both medications indicated as initial therapy for high blood pressure. When high blood pressure is not effectively controlled on a single medication they can be used in a combination.
Alistair Darling, Baron Darling of Roulanish, 70, British politician, chancellor of the Exchequer (2007–2010), MP (1987–2015) and member of the House of Lords (2015–2020). 1 December – Brigit Forsyth, 83, Scottish actress (Whatever Happened to the Likely Lads?, Boon, Still Open All Hours). 10 December – Willie McCulloch, 75, Scottish football player (Alloa Athletic, Airdrieonians) and manager (Cowdenbeath). (death announced on this date) 14 December – Hanzala Malik, 67, Scottish politician, MSP (2011–2016). (death announced on this date) 19 December – Sir Norman Arthur, 92, British military officer and Olympic equestrian (1960), GOC Scotland (1985–1988) and Lord Lieutenant of Kirkcudbright (1996–2006). (death announced on this date) 27 December – Jack McLean, 78, Scottish journalist and art teacher.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.